anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pulmonary hypertension (PH) is a chronic lung disease characterized by the progressive pulmonary vascular remodeling with increased pulmonary arterial pressure and right ventricular failure. Pulmonary vascular remodeling involves the proliferation, migration, and resistance to apoptosis of pulmonary artery smooth cells (PASMCs). Parthenolide (PTN) is a bioactive compound derived from a traditional medical plant feverfew (Tanacetum parthenium), and it has been studied for treatment of pulmonary fibrosis, lung cancer, and other related ailments. However, the function of PTN in the treatment of PH has not been studied.
PURPOSE: This study aimed to evaluate the anti-proliferation and pro-apoptosis effects of PTN on PH and investigate its potential mechanisms.
METHODS: An in vivo hypoxia-induced pulmonary hypertension (HPH) model was established by maintaining male rats in a hypoxia chamber (10% O2) for 3 weeks, and PTN was intraperitoneally administered at the dose of 10 or 30 mg/kg. We assessed the impact of PTN on mean pulmonary arterial pressure (mPAP), pulmonary vascular remodeling, and right ventricular hypertrophy. In vitro, we evaluated hypoxia-induced cellular proliferation, migration, and apoptosis of rat PASMCs. Proteins related to the STAT3 signaling axis were analyzed by western blotting and immunofluorescence assays. Recovery experiments were performed using the STAT3 activator, colivelin TFA.
RESULTS: PTN significantly alleviated the symptoms of HPH rats by attenuating pulmonary arterial remodeling. It also prevented the proliferation and migration of PASMCs. PTN also induced the apoptosis of PASMCs. PTN could directly interact with STAT3 and markedly inhibited STAT3 phosphorylation and nuclear translocation. In vitro, and in vivo experiments demonstrated that overexpression of STAT3 partially suppressed the effect of PTN.
CONCLUSION: Our study indicated that PTN alleviated hypoxia-induced pulmonary hypertension in rats by suppressing STAT3 activity.
The group of inventions relates to medicine, and more particularly to biomedical and information technology used in the health industry. The claimed system comprises a computer-readable data carrier with computer-readable instructions which implement a method comprising the steps of: obtaining personal data about a user; obtaining data about activities that improve the quality of life of an individual; processing the user data obtained, which includes calculating social factors and medical factors on the basis of the data obtained; processing the activity data, which includes generating a list of activities and identifying contraindications for each activity from the list of activities; and analyzing the data processed. This analysis includes using a predictive model with the aid of a random forest algorithm. Data analysis includes identifying correlations between social factors and medical factors by comparing said factors on a timeline. Each social factor is weighted according to its impact on each medical factor. A list is determined of critical activities leading to a deterioration in the quality of life of the user below a given level. A prediction of the user's quality of life is generated. Said quality of life prediction is displayed to the user. A list of recommended activities for improving the user's quality of life is generated and displayed to the user. Analysis of the current state of the user is carried out, which includes obtaining data about the current state of the user, including photoplethysmographic data, data about the physical activity of the user, and data about the electrical conductivity of the user's skin. The data about the current sate of the user is analyzed. Measurements are input into the predictive model. The quality of life prediction is adjusted, wherein if the quality of life prediction of the user declines, the user receives a notification about the need for a change in behaviour. The current state of the user is analyzed with a second periodicity that is more frequent than the first periodicity. The inventions effectively improve quality of life by virtue of using an individual approach to the evaluation of the state of a user, based on regular monitoring of the state of the user, of different aspects of the user's life and also of the proper application of the prescriptions given.
<P>PROBLEM TO BE SOLVED: To provide a method for intervening into a CD40L-mediated CD40 signaling pathway bearing the important roll in the maintenance of normal immunization when accommodative insufficiency is caused.  <P>SOLUTION: Methods of therapy for treating a subject for an autoimmune disease and/or inflammatory disease are provided. The methods comprise a step for administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits CD40L-mediated stimulation of CD40-expressing cells, and thus inhibits survival of the human CD40-expressing cells and signaling pathways of the human CD40-expressing cells that are mediated by CD40L.  <P>COPYRIGHT: (C)2011,JPO&INPIT
AIM: To show clinical characteristics, treatments, and comorbidities in chronic cough in a nationwide cohort.
METHODS: Two cohorts were created. A national cohort with individuals from two population-based databases; the National Patient Register and Swedish Prescribed Drug Register. Secondly, a regional cohort including primary care data. Adults with at least one cough diagnosis (ICD-10 R05) and/or individuals with ≥2 dispensed prescriptions for relevant cough-medication within the inclusion period, 2016-2018, were identified. Individuals on medications which may instigate cough or suggest acute infection or diagnosed with conditions where cough is a cardinal symptom, were excluded. Those remaining were defined as having possible refractory or unexplained chronic cough (RCC/UCC).
RESULTS: Altogether 62,963 individuals were identified with possible RCC/UCC, giving a national prevalence of about 1%. Mean age was 56 years and 60% were females. Many (44%) of the individuals with possible RCC/UCC visited cough relevant specialist clinics during the study period, but less than 20% received a cough diagnosis. A majority (63%) had evidence of RCC/UCC in the 10 years prior to inclusion in the study. In the regional cohort, including primary care data, the prevalence of RCC/UCC was doubled (2%). Cough medicines were mainly prescribed by primary care physicians (82%).
CONCLUSION: Most individuals with possible RCC/UCC sought medical care in primary care, and had a long history of cough, with various treatments tried, indicating a substantial burden of the condition. Referrals to specialist care were very rare. The results underline the need for a structured multidisciplinary approach and future therapeutic options.
The present invention relates to a burn treating powder of Chinese patent medicine for treating burns, which is prepared from 10g of bletilla tuber, 20g of rhubarb, 10g of yellow phase, 10g of garden burnet root, 20g of myrrh and 5g of borneol. The preparation method comprises the step: various kinds of traditional Chinese medicine are ground in proportion according to a prescription and uniformly applied on the wound surfaces of burns. The present invention is prepared from a plurality of traditional Chinese medicine which are ground and applied on the wound surfaces of burns. The present invention can alleviate pains and relieve leakage immediately. The product contains a plurality of medicine ingredients, can resist bacteria and relieve inflammation, promotes the healing of wound surfaces, shortens course of disease and reduces cicatrization. The present invention has no toxic side effect, lightens pains of patients largely and thus has broad market prospect.
A method of aiding detection of breast cancer by computer analysis of a mammogram image includes computing filtered second spatial derivative of intensity values at the pixels of the image, in the form of a Laplacian. The filtering is iterative adaptive smoothing of the first spatial derivative, which smoothing is applied to achieve relatively great smoothing effect where there is relatively little local variation in derivative value and a relatively small or no smoothing effect where there is relatively great local variation in derivative value. This has the effect of preserving locations of zero crossings in the Laplacian which correspond to edges or boundaries in the image. Regions of negative Laplacian value are labelled and connected. These labelled regions are locally bright spots in the image. From the preserved boundary locations of these locally bright spots, a plurality of feature measures are computed, indicative of their respective brightnesses, shapes and edge contrasts. Those locally bright spots having a weighted combination of logarithms of these feature measures exceeding a predetermined value are identified as microcalcifications of a type associated with cancer, and it is detected where such identified microcalcifications are grouped in clusters.
Maintaining lifelong adherence to HIV care is a major challenge for older adolescents and young adults (young people) living with HIV in sub-Saharan Africa where HIV infection is globally most prevalent. Innovative, low cost, and easily scaled strategies are urgently needed to improve young people's engagement to HIV treatment and reduce the public health consequences associated with nonadherence including secondary transmission of HIV infection. Modern mobile health (mHealth) interventions improve adherence to care among young people but are currently not feasible for many low-resource areas of sub-Saharan Africa. This includes theory-driven applications that use gamification, where real-life adherence behaviors are combined with interesting story-lines in a mobile game to promote HIV treatment engagement. Whereas web and smartphone access can be limited, traditional cellphones and text messaging are near universal and have been used previously to promote adherence through simple reminders and linkage to staff support in sub-Saharan Africa. However, to date, no text message adherence intervention has been enhanced through the use of gamification. To increase access to this potentially powerful intervention approach, the current study will test a novel mHealth intervention that uses text messages to gamify adherence behavior among YPLH in Ghana. Piloting this intervention will provide information on its feasibility and signs of preliminary efficacy. The ultimate goal following is further evaluation and refinement will be to disseminate the intervention on a large scale across Ghana and other areas of sub-Saharan Africa.
PURPOSE:To obtain the titled pigment which is excellent in adherability, extensibility, dispersibility, miscibility, ultraviolet absorbing properties, sunscreen-inhibiting effect, touch, safety to the skin, etc., by coating the surface of a pigment particle with a polyvalent metal salt of a specified acid. CONSTITUTION:A base pigment such as talc, kaolin or calcium carbonate is dispersed in an aq. soln. of 0.1-20wt% (based on the quantity of the pigment) water-soluble polyvalent metal salt of formula I (wherein M is Al, Mg, Zn, Ca, Zr; X is Cl, NO3, SO4, CH3COO; n is the valence of M). A 0.01-20wt%. aq. soln. of 1-4 equivalents (per equivalent of the polyvalent metal salt) of a p-methoxycinnamate of formula II (wherein M is Na, K, NH4) is added dropwise thereto. After the completion of the addition, the pH of the soln. is adjusted to an alkaline side and stirring is continued to deposit a polyvalent metal salt of p-methoxycinnamic acid of formula III on the surface of the pigment particle. The reaction mixture is filtered and the product is washed with water to completely remove deposited unreacted materials and dried, and if necessary, it is crushed.
Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
Prostate-specific antigen (PSA) is the most commonly used serum marker for prostate cancer. It plays a role in cancer detection, treatment monitoring, and more recently, in guiding adaptive therapy protocols, where treatment is alternated based on PSA levels. However, the relationship between PSA levels and tumor volume remains poorly understood. Empirical evidence suggests that different cancer cell types produce varying amounts of PSA. Despite this, current mathematical cancer models often assume either that all cell types contribute equally to PSA levels or that only certain subpopulations produce PSA at fixed rates. In this study, we compare Zhang et al.'s classical adaptive therapy protocol with the standard of care, which involves continuous maximum tolerable dose treatment, under different assumptions regarding PSA production. Specifically, we explore the possibility that testosterone-dependent, testosterone-producing, and testosterone-independent cells contribute to PSA production to varying degrees. We use the time to competitive release as a proxy for the time to disease progression. Our findings indicate that adaptive therapy consistently results in a longer time to competitive release compared to the standard of care, regardless of the assumptions about PSA production. However, when testosterone-independent cells are the sole PSA producers, Zhang et al.'s adaptive therapy protocol becomes inapplicable, as PSA levels never fall to half of their initial value, preventing therapy discontinuation. Additionally, we observe that the number and duration of treatment cycles in adaptive therapy are highly sensitive to assumptions about how much each cell type contributes to PSA production. Overall, our results emphasize the need for a deeper understanding of patient-specific PSA dynamics, which could enhance the effectiveness of adaptive therapy in prostate cancer treatment.
Patients with homozygous familial hypercholesterolemia has very high serum cholesterol levels despite receiving lipid lowering drugs (e.g. statins, etc). Most of such patients die before the age of 20 due to myocardial infarction, etc. Orthotopic liver transplantation (OLT) is an effective treatment and can decrease their serum cholesterol to near normal levels (Bilheimer DW, N Engl J Med 1984; 311:1658-64). Shortage of donor organ is a major problem for OLT. Hepatocyte transplantation is an alternative to OLT that may help to overcome the shortage of donor organ. There have been reports of successful treatment of different kinds of metabolic liver disorders (such as Crigler Najjar Syndrome (Fox IJ, et al. N Engl J Med 1998;338:1422-6), Factor VII deficiency (Dhawan A et al. Transplantation 2004:78:1812-4), Glycogen storage disease type Ia (Muraca M, et al. Lancet 2002;359:317-8), etc) by hepatocyte transplantation. The major problem with hepatocyte transplantation is that the source of hepatocytes is very limited. Bone marrow stem cells are the potential source of hepatocytes. Although, in the in-vivo system there is a controversy that if stem cells transdifferentiate into hepatocytes or fusion of stem cells and hepatocytes occur, however, in the in-vitro culture system successful and efficient transdifferentiation of mesenchymal stem cells into hepatocytes has been documented (Lee KD, et al. Hepatology 2004;40:1275-1284; \& Banas A, et al. Hepatology. 2007;46:219-28). We have already shown that infusion of mesenchymal stem cells is safe and feasible in cirrhosis (Mohamadnejad M, et al. Arch Iran Med 2007; In Press). In this study, 2 female patients with homozygous familial hypercholesterolemia will be included. The bone marrow of ABO compatible healthy male volunteers with a normal lipid profile will be taken, then bone marrow mesenchymal stem cells (MSCs) will be cultured, and then MSCs will be trans-differentiate into hepatocytes in the in-vitro culture system. Then the cells will be infused through the portal vein into the patients. The duration of follow up will be 6 months post-transplantation.
The intervention, MAC, is a seven-session (45- 60 minutes per session) psychotherapy intervention delivered via videoconference and/or telephone by licensed social workers. All sessions will be audio-recorded. MAC content, structure, and length are consistent with core components of cognitive behavioral therapy (CBT) (Freeman, 2004).
Prodn. of polydehydroaspartic acid (I) comprises heating aspartic acid (II) in presence of high b.pt. solvent (esp. diphenyl ether) and of a strongly-acid ion-exchange resin at 200-230 degrees C and normal pressure for 2-4 hr. (I) is an intermediate for mixed amide derivs. of polyaspartic acid (see FR 2424292) which are useful as adjuvants in cosmetics. Process gives practically quantitative yields of good coloured prod. and use of diphenyl ether instead of the conventional tetralin reduces reaction time. Solid catalyst makes prod. sepn. easy and the solvent and catalyst can be recycled (up to 5 times without purifcn.).
FIELD: medicinal microbiology. SUBSTANCE: for preparing leptospirosis vaccine no containing rabbit protein new strain Leptospira interrogans "Rat 2" НИИЭМ No. 466 is proposed. Strain is able to multiply actively on semisynthetic medium with human protein and shows stable virulence and high immunogenicity. Leptospira strain allows to prepare leptospirosis vaccine purified off mammalian protein showing high antigenic and protective properties for human immunization against interohemorrhagic leptospirosis. EFFECT: improved method of vaccine preparing. 1 tbl
NEW MATERIAL:A compound of formula I (X is O or S; Y is 1-methylhydroxyethylidene, etc.; Z is a H or a protecting group, e.g. an alkali, etc.; R is acetyl, etc.; the part of the dotted line is a single or double bond). EXAMPLE:p-Nitrobenzyl 3-(acetoxymethyl)-6-(R)-(2-oxo-4-methyl-1,3-dioxolan-4-yl)- 7- oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylate. USE:An antimicrobial agent. PROCESS:A silyl group is removed from a compound of formula II, and phosgene is reacted with the resultant compound. The reaction product is then oxidized to give a compound of formula III, which is then reacted with a nucleophilic reagent, etc. and oxidized. The protecting group is then removed to afford a compound of formula IV. A glyoxylic acid ester, etc. is then reacted with the compound of formula IV, and the OH group is substituted by a halogen. The resultant compound is then reacted with triphenylphosphine to afford the compound of formula V, which is then heated to carry out the ring closure and give the aimed compound of formula I (Y is 2-oxo-1,3-dioxolan-4-yl).
This study will investigate the effects of an additional 3,4-methylenedioxymethamine (MDMA)-assisted therapy session in up to three participants with PTSD who relapsed after their PTSD symptoms had significantly decreased during MAPS' initial U.S. Phase 2 trial testing the use of MDMA-assisted therapy in subjects with chronic, treatment-resistant posttraumatic stress disorder PTSD). This new protocol will consist of a single, full-dose open-label session of MDMA-assisted therapy, along with associated non-drug preparation and integrative therapy sessions.

MDMA is an investigational drug that was studied in a randomized, placebo-controlled study in 21 participants, and it included a final evaluation of symptoms at least one year after taking part in the study. While PTSD symptoms in most study subjects stayed at the same levels from when they completed the study, symptoms had returned in a few people. This open-label study is intended to see if an additional MDMA-assisted session conducted at least 14 months after the first sessions can help reduce PTSD symptoms.

The MDMA-assisted therapy session will be conducted by a male and female co-therapist team, one a psychiatrist and the other a psychiatric nurse. Vital signs (blood pressure, pulse and body temperature) and psychological distress will be measured throughout the experimental session. After the experimental session they will spend the night in the clinic with an attendant on duty, and complete a measure of alterations in consciousness, the States of Consciousness Questionnaire (SCQ) on the evening or day following the experimental session. Participants will meet with the investigators the next morning for an integrative therapy session before leaving the clinic. During integrative therapy sessions they will receive support in integrating their experiences and insights from the MDMA-assisted therapy session. There will be daily phone contact with one of the investigators for 7 days after the experimental session. Symptoms of PTSD, depression and general function will be assessed two months after the experimental session. There will be a long-term follow up with repeated outcome measures 12 months after the experimental session
A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (α-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area.
The hypothalamus controls food intake by integrating nutrient signals, of which one of the most important is glucose. Consequently, impairments in hypothalamic glucose-sensing mechanisms are associated with hyperphagia and obesity. Environmental enrichment (EE) is an animal housing protocol that provides complex sensory, motor, and social stimulations and has been proven to reduce adiposity in laboratory mice. However, the mechanism by which EE promotes adiposity-suppressing effect remains incompletely understood. Neurotrophic factors play an important role in the development and maintenance of the nervous system, but they are also involved in the hypothalamic regulation of feeding. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are expressed in the hypothalamus and their expression is stimulated by glucose. EE is associated with increased expression of Bdnf mRNA in the hypothalamus. Therefore, we hypothesized that EE potentiates the anorectic action of glucose by altering the expression of neurotrophic factor genes in the hypothalamus. Male C57BL/6 mice were maintained under standard or EE conditions to investigate the feeding response to glucose and the associated expression of feeding-related neurotrophic factor genes in the hypothalamus. Intraperitoneal glucose injection reduced food intake in both control and EE mice with a significantly greater reduction in the EE group compared to the control group. EE caused a significantly enhanced response of Gdnf mRNA expression to glucose without altering basal Gdnf mRNA expression and Bdnf mRNA response to glucose. These findings suggest that EE enhances glucose-induced feeding suppression, at least partly, by enhancing hypothalamic glucose-sensing ability that involves GDNF.